All In Biotech

Drug Trial Radar · NCT06095388

Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

Phase I/II Study of Weekly Infusions of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Actual

Start

Oct 4, 2023

Primary completion

Oct 31, 2029

Study completion Oct 31, 2029

Sponsor

Lead sponsor
JCR Pharmaceuticals Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I/ II, open-label, randomized, 2-arm study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIA patients.

Conditions

  • Mucopolysaccharidosis III-A

Interventions

  • JR-441Drug

    IV infusion

  • JR-441Drug

    IV infusion

  • JR-441Drug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the tolerability of JR-441 in MPSIIIA patientsTime frame: up to 5 years (multiple visits)
  2. To assess the safety of JR-441 in MPSIII-A patientsTime frame: up to 5 years (multiple visits)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.